HTA157 Reflection on Medicines That Have Recently Come Off Patent and Have Been Rejected by NICE in the Past 20 Years: A Case Study of Abiraterone for Treating Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (MHSPC)

Abiraterone is a drug used for treating metastatic hormone sensitive prostate cancer (mHSPC). The combination of Abiraterone Acetate plus Prednisone (AAP) with the standard Androgen Deprivation Therapy (ADT) showed a better clinical outcome. Abiraterone received a negative recommendation from the National Institute for Health and Care Excellence (NICE) in 2021 due to its high cost. The cost of Abiraterone is expected to decrease after the brand's patent expires in September 2022 and this is anticipated to affect NICE ’s decision.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research